Lip-Bu Tan Joins 4baseCare Advisory Board to Drive Precision Oncology Solutions

Tan is also the anchor investor and advisor at Yali Capital, which recently led 4baseCare’s $6 million Series A funding round.

4baseCare, an Illumina Accelerator company specializing in precision oncology through advanced genomics and digital health technology, has announced the addition of Lip-Bu Tan to its advisory board.

Tan, a seasoned venture capitalist with over 30 years of experience in deep tech, is the Chairman of Walden International and Founding Managing Partner of Walden Catalyst Ventures.

Tan’s extensive background in venture capital and deep tech is expected to enhance 4baseCare’s strategic growth significantly.

He is also the anchor investor and advisor at Yali Capital, which recently led 4baseCare’s $6 million Series A funding round.

Tan’s involvement with 4baseCare reflects his ongoing commitment to advancing precision medicine, particularly in regions where genomic data has been underrepresented.

Commenting on his new role, Tan stated, “4baseCare’s test meets a very large unmet need in the Asian and Middle Eastern markets where treatment decisions for cancer have primarily relied on genomic data from Caucasian populations. 4baseCare is bridging this critical genomics data gap in these regions, and I believe that it has the potential to make a big difference in the treatment approaches used in cancer.”

Hitesh Goswami, CEO and Co-Founder of 4baseCare echoed Tan’s sentiments, emphasizing the value of his experience as the company enters its next phase of growth.

“Lip-Bu Tan’s extensive experience as a venture capitalist will be incredibly valuable as we expand to new markets, build a sustainable company, and impact the lives of millions in need of cancer care.”

The startup’s advisory board includes experts in genomics and technology, and it recently welcomed Francis deSouza, a Silicon Valley veteran and former CEO of Illumina, as a key addition.

In the coming months, 4baseCare plans to establish genomics laboratories in the Philippines, Nepal, and Dubai.

The company will continue to build on its genomics and digital health solutions, focusing on advanced data analytics, improved clinical insights, and data-driven treatment recommendations to enhance cancer care globally.

The startup also reports that since its inception, 4baseCare’s genomic tests have impacted over 10,000 cancer patients across Southeast Asia, and the startup seeks to continue to push the boundaries of personalized oncology care.